72.29

0.01% 0.01

Ani Pharmaceuticals Inc (ANIP)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Ani Pharmaceuticals Inc stock is traded at $72.29, with a volume of 333.92K. It is up +0.01% in the last 24 hours and down -1.77% over the past month. ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.

Previous Close:

$72.28

Open:

$72.65

24h Volume:

333.92K

Relative Volume:

0.95

Market Cap:

$1.66B

Revenue:

$923.71M

Net Income/Loss:

$84.68M

P/E Ratio:

18.34

EPS:

3.9419

Net Cash Flow:

$182.81M

1W Performance:

-2.17%

1M Performance:

-1.77%

6M Performance:

-7.40%

1Y Performance:

-21.38%

1-Day Range:

$71.50

$73.08

1-Week Range:

$69.90

$74.28

52-Week Range:

$69.58

$97.00

Ani Pharmaceuticals Inc Stock (ANIP) Company Profile

Name

Ani Pharmaceuticals Inc

Sector

Healthcare (1052)

Industry

Drug Manufacturers - Specialty & Generic (84)

Phone

(609) 759-1810

Address

104 CARNEGIE CENTER DRIVE SUITE 300, PRINCETON, MN

Employee

970

Twitter

Next Earnings Date

2026-11-06

Latest SEC Filings

ANIP's Discussions on Twitter

Compare ANIP vs TAK, TEVA, HLN, ZTS, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ANIP Ani Pharmaceuticals Inc	72.29	1.66B	923.71M	84.68M	182.81M	3.9419
TAK Takeda Pharmaceutical Co Adr	19.67	62.84B	29.91B	1.30B	3.49B	0.4056
TEVA Teva Pharmaceutical Industries Ltd Adr	41.50	48.40B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	10.13	44.55B	14.54B	2.22B	2.58B	0.4871
ZTS Zoetis Inc	79.38	32.80B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	533.12	22.87B	3.17B	1.29B	1.01B	27.09

Ani Pharmaceuticals Inc Stock (ANIP) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-23-26	Initiated	Oppenheimer	Perform
Sep-09-26	Initiated	Leerink Partners	Outperform
Jul-17-26	Initiated	Canaccord Genuity	Hold
Jul-10-25	Initiated	H.C. Wainwright	Buy
Mar-14-25	Initiated	Jefferies	Buy
Mar-12-25	Initiated	JP Morgan	Overweight
Dec-11-24	Initiated	Leerink Partners	Outperform
Oct-11-24	Initiated	Piper Sandler	Overweight
Mar-15-24	Initiated	CapitalOne	Overweight
Aug-22-23	Reiterated	H.C. Wainwright	Buy
Mar-01-23	Initiated	Guggenheim	Buy
Sep-07-22	Initiated	H.C. Wainwright	Buy
Nov-02-21	Initiated	Truist	Buy
May-07-20	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Sep-12-19	Initiated	Guggenheim	Buy
May-10-19	Downgrade	Raymond James	Strong Buy → Outperform
Oct-16-17	Reiterated	Canaccord Genuity	Buy
Jul-31-17	Initiated	Canaccord Genuity	Buy
Feb-22-17	Downgrade	ROTH Capital	Buy → Neutral
Jun-23-16	Initiated	Raymond James	Strong Buy
May-24-16	Downgrade	Standpoint Research	Buy → Hold
Nov-13-15	Initiated	Standpoint Research	Buy
Sep-28-15	Upgrade	ROTH Capital	Neutral → Buy
Aug-05-15	Reiterated	Oppenheimer	Outperform
Aug-04-15	Reiterated	ROTH Capital	Neutral
Jul-31-15	Reiterated	Oppenheimer	Outperform
Jul-15-15	Reiterated	ROTH Capital	Neutral
Jun-23-15	Reiterated	Oppenheimer	Outperform
May-18-15	Reiterated	ROTH Capital	Neutral
May-06-15	Reiterated	Oppenheimer	Outperform
Apr-10-15	Downgrade	ROTH Capital	Buy → Neutral
Feb-26-15	Reiterated	ROTH Capital	Buy
Feb-18-15	Reiterated	Oppenheimer	Outperform

View All

Ani Pharmaceuticals Inc Stock (ANIP) Latest News

Oct 13, 2026

Will ANI (ANIP) Beat Estimates Again in Its Next Earnings Report? - Zacks Investment Research

Oct 13, 2026

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar - Zacks Investment Research

Oct 13, 2026

Oct 06, 2026

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises - Zacks Investment Research

Oct 06, 2026

Oct 01, 2026